Smilow Cancer Hospital celebrates 10th anniversary
Smilow Cancer Hospital at Yale New Haven celebrates 10 years since it opened its doors to a new state-of-the-art inpatient and outpatient 500,000-square-foot cancer care facility. Since that day in October 2009, Smilow Cancer Hospital and Yale Cancer Center have risen to the top echelon as one of the nation’s comprehensive cancer research and care facilities, providing advanced care to patients and families and pioneering cancer research.
For Teens Living with Cancer, Keeping Life as 'Normal' as Possible
Yale New Haven Children's Hospital has opened the Lauren Telesz/Smilow Teen Center, to fill an important gap between pediatric and adult cancer care. The center dovetails with a larger goal to help improve survival rates for adolescents and young adults with cancer.
Smilow Cancer Hospital first in CT to perform new cancer treatment
Yale New Haven Health’s Smilow Cancer Hospital is the first hospital in Connecticut to use an innovative new immunotherapy called chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, according to a press release from the hospital. “CAR T is an exciting new form of immunotherapy for certain blood cancers that is proving effective in patients with certain recurrent or resistant blood cancers,” said Stuart Seropian, the co-director of Smilow Cancer Hospital’s CAR T-Cell Therapy Program, in the press release.
Smilow Cancer Hospital first in Connecticut to perform CAR T-cell therapy
One of the most promising new generations of cancer treatment called Chimeric Antigen Receptor (CAR) T-cell therapy is now available for patients at Smilow Cancer Hospital. CAR T-cell therapy is groundbreaking immunotherapy that can cure patients with certain blood cancers who have run out of treatment options. In Connecticut, the treatment is only available at Smilow Cancer Hospital in partnership with Yale Cancer Center.
Gift supports work on a stubborn cancer
Ginny Grunley became a patient of Roy S. Herbst, MD, PhD, after being diagnosed with a form of lung cancer associated with the EGFR gene mutation, also known as non-smoker’s lung cancer. Grunley and her husband Ken have given a million-dollar gift to support Herbst’s research.
Clinical trials take innovative approach
Since their arrivals at Yale within the past six years, Joseph Paul Eder, MD, and Patricia LoRusso, DO, have overseen a sharp increase in the number of clinical trials conducted by the Phase I Program at Yale Cancer Center. Bench investigators and the clinicians who design and conduct early-phase trials interact regularly, each sharing knowledge with the other that both strengthens the basic science and brings new discoveries to patients more quickly and effectively.
Gene sequencing at Yale finding personalized root of disease; new center opens in West Haven
Our genes define our individuality, including what diseases to which we may be susceptible. In just a few days, gene-sequencing machines can map all of a person’s genes, revealing the cause of a genetic illness and even suggesting the best possible treatment. On Monday, the Yale School of Medicine, partnering with Yale New Haven Hospital, took the next step toward personalized medicine, cutting the ribbon on its Center for Genome Analysis on Yale’s West Campus.
New Liver Cancer Program Launches at Smilow
In the last 10 years there has been a constant growth in the number of patient with primary liver cancer treated at Yale New Haven Hospital and at Smilow Cancer Hospital. Smilow is one of the few medical center able to offer to patients with primary liver cancer a comprehensive array of therapeutic approaches and personalized care, according to the needs of each patient. These considerations have justified the formation of a freestanding Liver Cancer Program.
In-house specialty pharmacy reduces medical errors, wait time
The addition of an in-house specialty pharmacy at a cancer center in Connecticut reduced the amount of time patients waited for oral cancer medications; prevented errors associated with filling, dispensing and taking oral chemotherapy; and improved overall quality of care, according to a study being presented at the Quality Care Symposium. “Prior to our in-house pharmacy, we had no idea what happened after we sent prescriptions to outside specialty pharmacies,” Kerin Adelson, MD, chief officer at Smilow Cancer Center Hospital at Yale School of Medicine, said in a press release. “Did the patient start treatment later than recommended? Did the patient take the right combination and on a consistent basis? These were all questions that affect quality and outcomes that we were not able to answer before. Now we can.”